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Nearly 100proteins are proposed to be substrates forGSK3,suggestingthatthisenzyme isa fundamentalregulator ofalmostevery
process in the cell, in every tissue in the body. However, it is not certain how many of these proposed substrates are regulated by
GSK3 in vivo.Clearly, the identiﬁcationofthephysiologicalfunctions ofGSK3 will be greatlyaided by theidentiﬁcationof its bona
ﬁde substrates, and the development of GSK3 as a therapeutic target will be highly inﬂuenced by this range of actions, hence the
need to accurately establish true GSK3 substrates in cells. In this paper the evidence that proposed GSK3 substrates are likely to be
physiological targets is assessed, highlighting the key cellular processes that could be modulated by GSK3 activity and inhibition.
1.Introduction
1.1. Why Identify Substrates?
Glycogen synthase kinase-3 (GSK3) was ﬁrst reported as a
glycogen synthase phosphorylating activity in rabbit skeletal
muscle (the third to be found, hence GSK3) [1]. GSK3 was
later identiﬁed as a major tau protein kinase [2]. These
substrates immediately focused attention on the importance
of GSK3 in glucose metabolism and neurodegeneration, and
these remain major areas of GSK3 research. Indeed GSK3
inhibitors, which were initially developed for the treatment
of diabetes, are now being investigated for the treatment
of Alzheimer’s disease, as well as many other conditions
[3–5]. These therapeutic programmes have arisen directly
from substrate identiﬁcation; however, more recently the
multitude of GSK3 substrates proposed in the literature has
lessened therapeutic interest in this enzyme. It is therefore
of great importance to establish beyond doubt what the
physiological targets of this enzyme are, not only to focus
therapeutic potential but also establish actual side eﬀects of
manipulating GSK3 activity.
1.2.ProblemswithFalse Positives. Itis reasonably straightfor-
ward to implicate a protein as a substrate for a kinase, with
evidence ranging from the existence of a consensus phos-
phorylation sequence in the primary structure of a protein
through to regulation of phosphorylation by manipulation
of the protein kinase in vivo. Unfortunately, the existence of
a consensus sequence is rarely a good predictor of whether a
protein will be a substrate of that kinase. Indeed GSK3 target
consensus sequences occur in more than half of all known
human proteins, most of which are clearly not regulated by
GSK3. In addition, phosphorylation in vitro does not always
correlate with phosphorylation in vivo, and great care has
to be taken to characterise speciﬁcity of reagents, initial rate
kinetics, and stiochiometry of phosphorylation in vitro and
in vivo (see below).
1.3. Criteria for Conﬁdence. Establishing whether a proposed
substrate is a true physiological substrate of GSK3 is not
straightforward; however, three major criteria, if met, can
improve conﬁdence. Firstly, highly puriﬁed GSK3 (keeping
in mind that many commercial preparations are contami-
nated with copurifying kinases) should phosphorylate the
proposed substrate at a signiﬁcant rate in vitro (ideally in
comparison to other well-characterized substrates), and at
residues on the substrate that are phosphorylated in vivo.
Secondly, manipulation of GSK3 activity in cells and in
vivo (by genetic, pharmacological, and physiological means)
should change the phosphorylation of the speciﬁc residue
targeted by GSK3 in vitro (i.e., GSK3 inhibition should
speciﬁcally reduce phosphorylation of this site in cells).
Finally, a function of the substrate should change in parallel2 International Journal of Alzheimer’s Disease
to alteration of phosphorylation and cellular GSK3 activity,
while mutation of the GSK3 target residue to alanine should
render this function insensitive to GSK3 manipulation.
1.4. Speciﬁc Issues Relating to Addressing These Criteria for
GSK3 Substrates. Substrate phosphorylation by GSK3 in
vitro is complicated by the requirement for prephosphoryla-
tion (priming) of most characterised substrates [3, 6]. Puri-
ﬁed, bacterially expressed recombinant proteins will contain
little phosphate, and thus, if a substrate requires priming,
the bacterially expressed protein will not be phosphorylated
at an appreciable rate by GSK3 in vitro. Therefore, pre-
phosphorylation with an appropriate priming kinase is often
required in order to permit subsequent phosphorylation by
GSK3. In contrast the existence of this priming mechanism
provides the opportunity for additional validation of the
proteinas aGSK3substrate. Mutationofthe priming residue
toalanine,orinhibitionofthepriming kinasein cells,should
prevent subsequent phosphorylation by GSK3.
2.GSK3Biology
2.1. Gene Structure and Splicing. There are two GSK3 genes
(GSK3α and GSK3β) that account for all GSK3 activity in
mammals [7]. In addition, the GSK3β mRNA undergoes
alternative splicing that produces at least two diﬀerent
proteinproductsGSK3β1andGSK3β2.Thecatalyticdomain
is highly conserved between all GSK3 isoforms, although
GSK3β2 has a 13 amino acid insert in this domain [8–11].
GSK3α has an N-terminal glycine rich extension that results
in a larger relative molecular weight (51kDa for GSK3α,a n d
47kDa for GSK3β1, GSK3β2 exhibits intermediate mobility
upon SDS-PAGE of around 49kDa). GSK3α and GSK3β1a r e
ubiquitouslyexpressed [7], although relative expression does
vary from tissue to tissue (e.g., GSK3β is the predominant
isoform in brain [11]). In particular, the GSK3β2i s o f o r mi s
enriched in neuronsalthough the roleof thisvariant remains
unclear [8, 10].
2.2. Unusual Aspects of GSK3 Regulation and Substrate
Identiﬁcation. GSK3 is one of the few protein kinases to be
inhibited (as opposed to activated) following stimulation
of growth factor receptors. The basal activity of GSK3 in
restingcellsisrelativelyhighwhileexposureofcellstogrowth
factors, serum, or insulin reduces the speciﬁc activity of
GSK3 by between 30 and 70% (dependent on cell type and
stimuli) within 10mins. This appears the case for all GSK3
isoforms. Inhibition is predominantly achieved through
phosphorylation at a conserved N-terminal serine (Ser-21 in
GSK3α and Ser-9 in GSK3β)[ 12, 13], and growth factors,
promote GSK3 phosphorylation by activation of PKB or
p90RSK[14, 15] while insulin inhibits GSK3mainly through
PKB [14]. This indicates that phosphorylation of many bona
ﬁde GSK3 substrates should be reduced upon stimulation of
cells with serum, growth factors or insulin (Figure 1).
GSK3 is one of only a handful of the 500 mammalian
protein kinases that have a strong preference for sub-
strates that are already phosphorylated. Most of the best
described GSK3 substrates require pre-phosphorylation at
a residue 4 or 5 amino acids C-terminal to the GSK3
target residue (Table 1(a)), a phenomenon referred to as
PRIMING. Hence the general GSK3 substrate consensus
sequence is Ser/ThrXXX(PhosphoSer/Thr), where X is any
residue. However, proposed substrates of GSK3 exist that
do not conform to this sequence, having either a priming
site much further from the t a r g e ts i t e ,o rn oa p p a r e n t
requirement for priming at all (Table 1(a)). It is not yet
clear how GSK3 recognises unprimed substrates; however, in
almosteveryexampleofprimedsubstratethelackofpriming
reduces phosphorylation by GSK3 by >90%, demonstrating
the importance of the phosphorylated residue C-terminal
to the target site. Priming also allows the regulation of the
GSK3-substrate reaction by N-terminal phosphorylation of
GSK3. GSK3 has a phosphate binding pocketwhich interacts
with the substrate at the primed Ser/Thr and positions it
for phosphorylation by GSK3. Phosphorylation of Ser-21/9
of GSK3α/β results in the N-terminal domain of GSK3
interacting with its phosphate binding pocket, preventing
recognition of primed substrates [6]. This inhibition can
be overcome by increasing substrate concentration (at least
in vitro) ,a n di ts u g g e s t st h a tm o d u l a t i o no ft h i sa s p e c t
of regulation (e.g., by growth factors) would not inhibit
phosphorylation of unprimed substrates (Figure 1)[ 6].
The semaphorin family of axonal guidance molecules
induces GSK3 activity at the leading edge of migrating cells
through the dephosphorylation of this N-terminal serine
[16, 17]. The mechanism is not fully elucidated but involves
activation of R-RAS(GAP) and the subsequent suppression
of R-Ras [17]. Again this mechanism of regulation sug-
gests that semaphorins regulate only primed substrates of
GSK3.
There are reports that GSK3 activity can be induced
by speciﬁc extracellular stimuli, and this regulation appears
to be particularly apparent in the brain [18]. In theory,
induction of phosphorylation at Tyr216 (GSK3β1n u m -
bering) is a mechanism for regulating GSK3 activity [18].
Phosphorylation of this tyrosine is crucial for proper folding
of the catalytic domain, and it occurs through autophos-
phorylation during synthesis of the GSK3 polypeptide [19].
As such Tyr216 is likely to be constitutively phosphorylated
to high stoichiometry [20], yet an increase in Tyr216 phos-
phorylation was observed in PC12 cells following removal
of NGF (and other apoptotic stimuli), correlating with
increased GSK3 activity [18]. However, this observation has
subsequently been challenged [20].
Interestingly, regulation of GSK3 by the canonical Wnt
signaling pathway does not involve N-terminal or tyrosine
phosphorylation [21] .W n tr e g u l a t i o no fG S K 3i sm o s tl i k e l y
achieved through disruption of a speciﬁc complex including
Axin/APC/β-catenin and GSK3 (Figure 1). This mechanism
has been well characterized for the phosphorylation and
degradation of β-catenin, and could in theory be as eﬀective
at inhibiting phosphorylation of unprimed substrates. In
addition, thispathwaydemonstratesthe existenceofseparate
intracellular pools of GSK3, since insulin will not regulate
β-catenin activity and Wnts will not regulate glycogen syn-
thesis [22–24]. Hence compartmentalization of GSK3 allowsInternational Journal of Alzheimer’s Disease 3
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Figure 1:Diﬀerent signalingpathwaysregulate GSK3activity by diﬀerent mechanisms,andthiscould permit diﬀerential regulation ofGSK3
substrate phosphorylation.
diﬀerential upstream regulation but also enables diﬀerential
downstream substrate phosphorylation (Figure 1).
Finally, the stress-induced p38MAPK family can phos-
phorylate Thr390 of GSK3β reducing its activity, and this
also contributes to canonical Wnt signaling and regulation
of substrates such as β-catenin [25, 26]. This is of particular
interest as the residue is not conserved in GSK3α and thus
provides a potential GSK3 isoform speciﬁc regulation.
3.GSK3Substrates:Physiological
FunctionandTherapeuticPotential
3.1. Genetic Studies to Elucidate GSK3 Function. Dele-
tion of the GSK3β gene in mice is lethal [144, 145],
while GSK3β heterozygous (+/−) mice exhibit reduced
aggression, increased anxiety, reduced exploratory activity,
poor memory consolidation, and reduced responsiveness
to amphetamine [146–148]. Conversely, overexpression of
GSK3β in brain results in hyperactivity and mania [149].
Mice lacking GSK3α are viable and relatively normal
[150], exhibiting a small improvement in insulin sensitivity
and glucose tolerance. Mice lacking GSK3α speciﬁcally in
neurons display reduced aggression and exploratory activity,
decreased locomotion, impaired co-ordination, and a deﬁcit
in fear conditioning [151]. The diﬀerential phenotypes
between isoform deletions suggest nonredundant functions
of the GSK3 genes in the brain, while the overlapping
behavioural problems between GSK3α neuronal knockout
(KO) and GSK3β (+/−) mice suggest some common sub-
strates.
Deleting both GSK3 isoforms in the brain induces self-
renewal of neuronal progenitor cells, but reduced neuroge-
nesis [152]. Mutation of the N-terminal regulatory serine to
alanine renders GSK3insensitive togrowthfactor regulation.
GSK3α/β double knockin mice (where both isoforms are
replaced by mutant proteins with Ser to Ala alterations at
Ser21 and Ser9, resp., [22]) show impairment of neuronal
precursor cell proliferation [153]. Taken together, these data
indicate that proper regulation of expression and activity
of GSK3 is required for maturation of these cells during
mammalian braindevelopment.However,thesubstratesthat
mediate this function are unknown. Conversely, overexpres-
sion of GSK3β in the brain (using the Thy1 promoter)
induces microcephaly [154, 155].
Alternative splicing of GSK3β between exon 8 and 9
gives rise to two main variants of this isoform [8]. GSK3β1
is the most widely expressed; however GSK3β2 (including
a 13 amino acid insert due to use of exon 8A) is highly
enriched within the brain [8]. The inserted sequence lies
within the kinase domain, and there is preliminary evidence
that these variants exhibit diﬀerential substrate speciﬁcity
[8, 9, 11]. However, how this impinges on GSK3 function
remains unclear.
Therefore,althoughgeneticablationofoneorbothgenes
for GSK3 has provided clues as to the cellular processes that
requireGSK3activity,ithasnotyetestablishedthemolecular
connections responsible for these phenotypes. Table 1(a)
lists more than 100 sequences within 77 proteins that are
proposed as substrates of GSK3, virtually none of these have
been examined in tissue from GSK3 null animals. Table 1(b)
lists the substrates from Table 1(a) where at least 2 of the 3
criteria for conﬁdence (as detailed in Section 1.3) have been
met. This represents around half of the sites and proteins
listed in Table 1a (all three criteria have been met for very
few substrates) and covers a variety of cellular processes, as
detailed below.4 International Journal of Alzheimer’s Disease
Table 1: (a) A list of proteins reported to be substrates for GSK3. Where the phosphorylation site, priming mechanism and functional
outcome of phosphorylation have been reported, this information is included. ND:not determined. (b) A list of those substrates from (a)
that meet at least two out of the three criteria for conﬁdence detailed in Section 1.3 of text, including cellular process likely to be regulated.
These are the substrates discussed in more detail in the review.
(a)
Proposed substrate Target residue(s) Priming residue (kinase) Eﬀect of phosphate Ref
Amyloid precursor protein Thr743 (APP770) ND Regulates traﬃcking [27–29]
Thr668 (APP695)
APC 1501 1505 (CK1) Regulates degradation [30, 31]
1503 1507 (CK1)
ATP-citrate lyase Thr446, Ser450 Ser454 (unknown) May regulate activity [32, 33]
Axin Ser322/Ser326 (putative) Ser330 Regulates stability [34, 35]
Axil Not Determined Not reported [36]
BCL-3 Ser394, Ser398 (ERK putative) Regulates degradation [37]
Ser398 (putative)
β-catenin Ser33, 37, Thr41 Ser45 (CK1) Regulates degradation [34]
δ-catenin Thr1078 (putative) ND Regulates degradation [38]
C/EBPalpha Thr222, Thr226 (Questioned) NONE NONE [39, 40]
C/EBPbeta Ser184, Thr179 Thr188 (MAPK) Induces DNA binding
Reduces DNA binding
[41]
Thr189, Ser185, Ser181, Ser177 NONE [42]
Ci-155 Ser852, Ser856 (PKA) Regulates Degradation [43, 44]
Ser884, 888 Ser892 (PKA)
CLASP Residues between 594 and 614 Alters aﬃnity for
microtubules [45, 46]
CLASP2 Ser533 and Ser537 (others) Ser541 (CDK5) Aﬀects protein-protein
interaction [47]
CRMP2 Thr509, Thr514, Ser518 Ser522 (CDK5)
Regulates axon growth,
growth cone collapse, and
neuronal polarity
[48, 49]
CRMP4 Thr509, Thr514, Ser518 Ser522
Regulates axon outgrowth
and chromosomal
alignment
[48, 50]
CREB Ser129 Ser133 (PKA) Kinase activation [51, 52]
CRY2 Ser553 Ser557
Promotes nuclear
localisation and
degradation
[53]
CTP: phosphocholine
cytidylyltransferase
Multiple, within C-term 52
residues ?N o e ﬀect on activity [54]
Cytidine triphosphate
synthetase (CTPS) Ser571 Ser575 Phosphorylationmay
reduce activity [55]
Cyclin D1 Thr286 NONE
Nuclear export and
degradation [56]
Questioned [57]
Dynamin I Thr774 Thr778 (CDK5)
Required for activity
dependent bulk
endocytosis
[58]
Dystrophin ND CKII ? Not reported [59]
eIF2B Ser535 Ser539 (DYRK) Inhibits activity [60–62]
FAK Ser722 Ser726 Inhibits activity [63]
Gephyrin Ser270 ND Modulates GABAergic
transmission [64]
Glycogen Synthase Ser640, 644, 648, 652 Ser656 (CKII) Reduces activity [65, 66]
Glucocorticoid receptor Thr171 (Not conserved in
human protein) NONE Inhibits GR activity
towards some genes [67]International Journal of Alzheimer’s Disease 5
(a) Continued.
Proposed substrate Target residue(s) Priming residue (kinase) Eﬀect of phosphate Ref
Heat shock factor 1 Ser303 Ser307 (MAPK) Reduces DNA binding [68]
HIF1alpha Ser551, Thr555, Ser589 ND Induces proteosomal
degradation [69]
Histone H1.5 Thr10 NONE
Coincides with
chromosome
condensation
[70]
hnRNP D Ser83 Ser87 Inhibits transactivation [71]
IRS1 Ser332 Ser336 Promotes degradation [72]
c-jun, Jun B, Jun D Thr239 Thr243 Reduces DNA binding [73–75]
K-casein ND ND Not reported [76]
KRP (telokin) Ser15 Unknown site but ERK2
proposed Not reported [77]
LRP6 C-terminal PPPT/SP motifs
(Ser1490, Thr1572, Ser1590) NONE Not clear [78, 79]
MafA Multiple sites, not identiﬁed ND
Phosphorylationinduces
MafA degradation and
prevents insulin gene
expression
[80]
MAP1B Ser1260, Thr1265 NONE Regulates stability
(lithium promotes
degradation)
[81–83]
Ser1388 Ser1392 (DYRK)
MAP2C Thr1620, Thr1623 ND Reduces microtubule
binding
[84]
MARK2/PAR1 Ser212 NONE Regulates activity [85, 86]
Mcl1 Ser140 Thr144 (JNK)
Permits degradation of
Mcl1 in response to UV
stress
[87–89]
Mdm2 Ser240, Ser254 Ser244, Ser258 (CK1) Promotes activity towards
p53, reducing p53 levels [90]
MITF Ser298 NONE Increases transactivation [91]
MLK3 Ser789, Ser793 ND Activates MLK3 Induces
apoptosis in PC2 cells [92]
MUC1/DF3 Ser40 (possible) Ser44 (possible)
Inhibits formation of
b-catenin-E-cadherin
complex
[93]
c-myb Thr572 ND Not clear [94, 95]
c-myc, L-myc Thr58, Thr62 (c-myc) Ser62 (ERK1/2) Promotes degradation [96–98]
Myocardin 8 serines in two blocks,
Ser455—467 and Ser624—636
Yes but kinase not
reported
Phosphorylation inhibits
myocardin induced
transcription
[99]
αNAC (nascent
polypeptide associated
complex)
Thr159 NONE Induces transactivation,
maybe stability [100]
NDRG1 Thr342, Ser352, Thr362 Thr346, Thr356, Thr366
(SGK) Not reported [101]
neuroﬁlament L Ser502, 506, 603, 666 (M)
ND Not reported
[102]
neuroﬁlament M Ser493 (H) [103]( M )
neuroﬁlament H [104]( H )
NFAT
SRR domain ND
Induces nuclear exclusion,
inhibits DNA binding [105–107] SP-2 domain PKA or DYRK
SP-3 domain PKA
Ngn2 231 and 234 ND
Facilitates interaction with
LIM TFs, involved in
motor neuron
determination
[108]6 International Journal of Alzheimer’s Disease
(a) Continued.
Proposed substrate Target residue(s) Priming residue (kinase) Eﬀect of phosphate Ref
Notch 1C ND Stabilises protein [109]
Nrf2 ND Inhibits activity by nuclear
exclusion [110, 111]
OMA1 Thr339 Thr239 (MBK-2) Induces degradation [112]
p130Rb
Ser948 Ser952
Regulates stability Ser962 Ser966 [113]
Ser982 Thr986 all CDK putative
p21 CIP1 Thr57 ND Induces degradation [114]
p27Kip1 Not fully established ND Regulates stability [115]
p53 Ser33 (GSK3beta only) Ser37 (DNA-PK) Increases transcriptional
activity [116]
Ser315, Ser376 ND
Increases cytoplasmic
localisation,degradation,
inhibits apoptosis
[117]
p65 RelA Multiple, including Ser468 ND Negatively regulates basal
activity [118, 119]
PITK Ser1013 Ser1017 (CAMKII)
Induces nuclear
localization and possibly
interaction with PP1C
[120]
Polycystin-2 Ser76 Ser80
Regulates localisation,
enhanced in polycystic
kidney disease
[121]
PSF- Polypyrimidine
tract-binding protein-
associated-splicing
factor
Thr687 NONE
Regulates interaction with
TRAP-150, and CD45
alternative splicing in T
cells
[122]
Presenilin-1 Ser397, Ser401 NONE Reduces interaction with
β-catenin
[123]
Ser353, Ser357 [124]
Protein phosphatase1
G-subunit Ser38, 42 (human) Ser46 (PKA or p90RSK) Not clear [125]
Protein phosphatase
inhibitor 2 Thr72 Ser86 (CKII) Inhibits inhibitor, thereby
activating PP1
[11, 126,
127]
PTEN Ser362, Thr366 Ser370 (CK2) Possibly inhibits activity [128]
Pyruvate Dehydrogenase ND Inhibits activity [129]
RCN1 (yeast calcineurn
regulatory
protein-calcipressin)
Ser113 Ser117 Regulates cacineurin
signaling [130]
SC35 ND Probably Redistributes this splicing
factor [131]
SKN-1 Ser393, (maybe Ser389 and
Thr385) Ser397 Inhibits activity [132]
SMAD3 Thr66 ND Regulates stability [133]
Snail Ser97, 101, 108, 112, 116, 120 ND
Regulates degradation and
nuclear exclusion
(antitumourogenic)
[134]
SREBP1c (processed
fragment) Thr426, Ser430 ND Promotes degradation [135]
Stathmin Ser31 ND
Slight induction of
depolymerisation of
microtubules
[136]International Journal of Alzheimer’s Disease 7
(a) Continued.
Proposed substrate Target residue(s) Priming residue (kinase) Eﬀect of phosphate Ref
Tau
Multiple including Ser208,
Thr231, 235
Thr212 (DYRK)
Some phosphorylation
sites regulate microtubule
binding
[62, 137,
138]
Ser396
Ser404, others? [139]
TSC2 Ser1341, Ser1337 Ser1345 (AMPK) Activates TSC2 to inhibit
mTOR [140]
VDAC Thr51 Thr55
Modulates interaction
with HKII in
mitochondrial membrane
[141]
von Hippel-Lindau (VHL) Ser68 Ser72 (CKI) Regulation of MT
stabilization [142]
Zcchc8 Thr492 ND ND [143]
(b)
Proposed substrate Eﬀect of phosphate Cellular process
Amyloid precursor protein Regulates Traﬃcking Neurobiology
BCL-3 Degradation Growth and Survival
β-catenin Degradation Development
C/EBPbeta Regulates DNA binding Endocrine control
Growth and survival
Ci-155 Regulates degradation Development
CLASP2 Aﬀects protein-protein interaction Neurobiology/cell migration
CRMP2 Regulates axon growth, growth cone
collapse and neuronal polarity. Neurobiology
CRMP4 Regulates axon outgrowth Neurobiology
CREB Activation Neurobiology
Endocrine control
Cytidine triphosphate synthetase (CTPS) Reduces activity Cell growth
Dynamin I Required for activity dependent bulk
endocytosis Neurobiology
eIF2B Inhibits activity Cell Growth
FAK Inhibits activity Growth and Survival
Glycogen Synthase Reduces activity Endocrine control
heat shock factor 1 Reduces DNA binding Growth and Survival
HIF1alpha Induces proteosomal degradation Growth and Survival
Histone H1.5 Coincides with chromosome condensation Cell division
IRS1 Promotes degradation Endocrine control
c-jun, Jun B, Jun D Reduces DNA binding Growth and survival
MAP1B Regulates stability Neurobiology
MAP 2C Reduces microtubule binding Neurobiology
MARK2/PAR1 Regulates activity Neurobiology
Mcl1 Permits degradation of Mcl1 in response to
UV stress Growth and survival
Mdm2 Promotes activity towards p53, reduces p53
levels Growth and survival
c-myc, L-myc Promotes degradation Growth and survival
Myocardin Inhibits myocardin induced transcription Development
NDRG1 Not reported Ion control
NFAT Regulates nuclear exclusion, Inhibits DNA
binding Immunology
Ngn2 Facilitates interaction with LIM TFs, for
motor neuron determination Development
p130Rb Promotes stability. Growth and survival8 International Journal of Alzheimer’s Disease
(b) Continued.
Proposed substrate Eﬀect of phosphate Cellular process
protein phosphatase 1 G-subunit Not clear Endocrine control
protein phosphatase inhibitor 2 Inhibits inhibitor, thereby activating PP1 Endocrine control
Polycystin-2 Regulates localisation,induced in polycystic
kidney disease Growth and survival
PTEN Inhibits activity Growth and survival
RCN1 (yeast calcineurn regulatory protein) Stimulates cacineurin signaling Growth and survival
Neurobiology
Snail Induces degradation and nuclear exclusion
(antitumourogenic) Growth and survival
Tau Modulates interaction with tubulin
Increased in AD Neurobiology
VDAC Modulates interaction with HKII in
mitochondrial membrane Growth and survival
von Hippel-Lindau (VHL) Regulation of MT stabilization Neurobiology
Interestingly, onlyfouroftheproteinslistedinTable 1(b)
appear to have no requirement for priming (C/EBPbeta,
histone H1.5, MARK2, and tau (at some sites)). Thus, by
far the majority of the well-characterized substrates require
priming.
3.2. GSK3 in Energy Homeostasis. Glucose is a vital nutrient
for most mammalian cells. It is obtained by ingestion of
food but can be generated endogenously in the liver by
glycogenolysis or gluconeogenesis (from amino acids or
glycerol) during periods of fasting. These processes ensure
there is a constant supply of glucose in the blood (around
5mM), available to all cells in the body. However, high
glucose is relatively toxic to tissues and blood proteins,
hence there are complex endocrine mechanisms to prevent
hyperglycemia (diabetes). Insulin is released from pancreatic
β-cells in response to postprandial rising blood glucose, and
this hormone combats hyperglycemia by acting on liver,
muscle, and fat tissue, promoting glucose storage in the
form of glycogen, turning oﬀ hepatic gluconeogenesis and
promoting adipogenesis (for review see [156, 157]).
Loss of pancreatic β-cells is the main cause of Type 1
diabetes, as these cells are the only endogenous source of
insulin. Treatment with exogenous insulin at appropriate
times is relatively eﬀectivein restoring glucose control in this
condition.In contrast, Type 2 diabetes (accounting forabout
90% of diabetes) is less well deﬁned, and includes defects in
glucose sensing, insulin secretion, and loss of insulin action
(insulin resistance). Hencetreatment with exogenous insulin
is less eﬀective, and alternative approaches, such as insulin
sensitizing agents (e.g., metformin) are used to combat
this condition. GSK3, as its name indicates, has long been
associated with insulin regulation of glucose homeostasis
and as such has been investigated as a therapeutic target in
diabetes.
3.2.1. Glycogen Synthase. Phosphorylation of glycogen syn-
thase by GSK3 reduces glycogen synthesis (glucose storage)
in muscle. Glycogen synthase is constitutively phosphory-
lated by CKII at Ser656, providing initial priming for a
series of phosphorylation events by GSK3 (652, 648, 644,
640), each additional phosphorylation in turn adding to the
inhibition of glycogen synthase activity [1, 66]. This places
GSK3 in the pathway from insulin, to glucose disposal. More
recently, inhibition of GSK3 in cells [158]a n din vivo [159]
was found to reduce hepatic gluconeogenesis, although the
GSK3 substrate responsible for this action remains elusive.
Clearly, as GSK3 is inhibited in cells treated with insulin
pharmacological inhibition of GSK3 should mirror many
of the natural actions of insulin including reducing glucose
production and enhancing glucose storage to combat hyper-
glycemia. Therefore many major pharmaceutical companies
have generated potent and selective GSK3 inhibitors as
potential antidiabetes therapeutics and initial data in animal
models suggests eﬃcacy in glucose lowering [159, 160].
3.2.2. CREB and C/EBP. GSK3 also regulates a number of
transcription factors with links to endocrine action, in par-
ticular the transcription factors C/EBPβ and CREB, which
are responsive to hormones that stimulate the generation
of the second messenger cAMP [161, 162]o rt ot h ef a s t i n g
signal glucocorticoids [163]. The regulation of C/EBPβ by
GSK3 appears complex, with priming of Thr188 by ERK
allowing GSK3 to phosphorylate C/EBPβ and induce its
DNA binding [41]. Conversely, unprimed phosphorylation
ofdistinctresidues(albeitinthesame domainoftheprotein)
isreportedtoreduceDNAbinding[42],soitremainsunclear
which mechanism is invoked upon regulation of GSK3 in
vivo.
Meanwhile, phosphorylation of CREB at Ser129 by
GSK3, following priming by PKA at Ser133, is reported to
induce CREB transcriptional activity [51, 52]h o w e v e rt h e
regulation of key CREB-dependent genes by GSK3 in cells
or animals remains poorly studied.
In summary, there is little direct evidence that GSK3
regulates these transcription factors as part of physiological
responses to the hormones of glucose homeostasis.
3.2.3. Insulin Signaling. GSK3can regulate cellularphospho-
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a key regulator of insulin signaling. GSK3 phosphorylation
of Inhibitor-2, a regulator of PP1, antagonizes Inhibitor-2
function thereby inducing PP1 activity [11, 126, 127]. In
this way, inhibition of GSK3 would be predicted to reduce
PP1 activity and indirectly induce phosphorylation of cel-
lular proteins (and conversely overexpression of GSK3 may
reducephosphorylation ofsome proteins).In additionGSK3
phosphorylates the glycogen binding subunit of protein
phosphatase-1 (PP1G) following priming by PKA at Ser46,
although the eﬀect of phosphorylation on PP1G function is
unclear[125].Theseweretwooftheﬁrstsubstratesidentiﬁed
for GSK3 following closely behind glycogen synthase, and
hence added to the evidence that GSK3 played a key role in
regulation of glycogen metabolism in muscle. More recently
GSK3 has been implicated in a negative feedback regulation
ofinsulinsignaling,andhencepotentiallycontributingtothe
insulin resistance found in diabetes as well as other diseases
such as polycystic ovarian syndrome and nonalcoholic fatty
liverdisease. GSK3phosphorylates insulin receptorsubstrate
(IRS)-1 at Ser332, following priming at Ser336, thereby
promoting its degradation [72]. IRS-1 is a key target for the
insulin receptor tyrosine kinase [164], hence loss of IRS1
due to aberrant activation of GSK3 would reduce the insulin
signaling capacity of the cell.
In summary, GSK3 inhibition has the potential to
enhance cellular insulin sensitivity (stabilize IRS1), reduce
hepatic glucose production (target unknown) and promote
glucose disposal (glycogen synthase), all beneﬁcial to the
diabetic patient. Consistent with the molecular predictions,
inhibition of GSK3 in an animal model of diabetes reduces
the associated hyperglycemia and insulin resistance [159].
However, the ever-growing list of potential GSK3 substrates
involved in cell growth (see next section) has dampened the
enthusiasm for using GSK3 inhibition as a treatment for
a chronic condition such as diabetes (where patients may
require treatment for 10–50 years).
3.3. GSK3 in Growth and Survival. The numerous proposed
substrates of GSK3 with a role in the control of cell growth
and survival suggests that pharmacological manipulation
of GSK3 activity may increase the risk of abnormal cell
growth or diﬀerentiation; however many of these proposed
substrates remain poorly characterised.
3.3.1. Bcl3. Bcl3 is a member of the I
￿Bf a m i l yo fN F
￿B
inhibitorsthatinducestranscription ofmanygenesincluding
cyclinD1[165]. ConstitutiveBcl3phosphorylation atSer394
by GSK3 (possibly following priming at Ser398) promotes
its degradation [37]. Bcl3 expression is upregulated in many
tumours, thus GSK3 is proposed to keep the oncogenic
potential of Bcl3 in check.
3.3.2. c-Jun. The proto-oncogene c-Jun is one of the compo-
nentsofAP-1,a transcription factorcomplexbelievedtoplay
key roles in cell proliferation, survival and death (reviewed
in [166, 167]). It is regulated by multisite phosphorylation
including N-terminal phosphorylation which induces its
transcriptional activity, and C-terminal phosphorylation
which inhibits its binding to DNA. JNK and ERK phospho-
rylate the N-terminal siteson c-juntoactivate it, while GSK3
phosphorylates Thr-239 to inhibit c-jun activity (following
priming of Ser243 by an unknown kinase) [73–75]. Hence
GSK3 inhibitionwould potentially enhance the action of this
oncogene.
3.3.3. Mcl-1. Mcl-1 is an antiapoptotic member of the Bcl2
family that is essential for embryonic development and for
the survival of hematopoietic cells. Mcl-1 playsan important
roleinthesensitization ofcellstoapoptoticsignals. Exposure
to UV radiation causes the rapid degradation of Mcl-1 and
the release of proapoptotic partner proteins (e.g., Bim). In
response to UV (and other cell stress) JNK phosphorylates
Mcl-1 at Thr144 priming it for subsequent phosphorylation
by GSK3 at Ser140. JNK and GSK3 activities are required for
degradation of Mcl-1 in response to stress [87–89], so GSK3
inhibition would antagonize this apoptotic mechanism.
3.3.4. Mdm2. The Mdm2 oncoprotein regulates abundance
and activity of the p53 tumor suppressor protein. Phos-
phorylation of Mdm2 at several contiguous residues within
the central conserved domain is key to this function.
GSK3 phosphorylates Mdm2 in the central domain both in
vitro and in vivo [90]. Inhibition of GSK3 prevents p53
degradationinanMdm2-dependentmanner, andexpression
of a S9A GSK3 mutant reduces the accumulation of p53
and inductionofitstargetp21(WAF-1).Therefore inhibition
of GSK3 could promote hypophosphorylation of Mdm2
resulting in stabilization of the tumour suppressor p53 [90].
3.3.5. c-Myc. c-Myc is an immediate early gene controlling
cell proliferation, diﬀerentiation, and apoptosis. It can be
primedatSer62byERK2(extracellularsignal-related protein
kinase 2), allowing phosphorylation at Thr58 by GSK3,
which targets c-Myc for ubiquitin-mediated proteolysis
[96]. Thus mitogen-induced dephosphorylation of c-Myc
at Thr58 may increase its half-life, similar to the situation
proposedfor(butlesswellcharacterized for)cyclinD1[168].
Thr58 ismutatedinallv-Mycproteins,andrestorationofthe
wild-type threonine severely inhibits transforming potential
[169]. Moreover, the T62A mutant c-Myc (GSK3 resistant)
potentiates focus formation [170]. There is good evidence
that GSK3 is responsible for Thr58 phosphorylation in vivo.
Firstly, CT99021, a selective GSK3 inhibitor, reduces c-Myc
phosphorylation at Thr58 in cells, secondly, c-Myc protein
is elevated in GSK3β KO brain, and ﬁnally, overexpression
of GSK3β in HEK293 cells increases Thr58 phosphorylation
[11]. This suggests that GSK3 inhibition in vivo would
enhance the stability of this oncogenic factor.
Paradoxically, mutation of Ser62 to Ala is reported to
destabilizec-Myc,suggestingthatthephosphorylationofthis
residue may stabilize c-Myc and as such play an opposing
role to the phosphorylation of Thr58. Thus the regulation
of c-Myc by serum appears to run a ﬁne line between
stabilization and degradation. Activation of PI 3-kinase
and ERK by serum will induce Ser62 phosphorylation but
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is consistent with the observation that the half-life of c-
Myc increases in response to serum [171]. One presumes
that upon serum withdrawal, GSK3 activity increases and
phosphorylation of the already primed c-Myc enhances the
rate of its degradation [96–98].
3.3.6. p130 Retinoblastoma Protein (Rb). The interaction
of p130Rb with E2F transcription factors results in active
repression of E2F-dependent genes (key for DNA synthesis
and cell cycle progression as well as diﬀerentiation and DNA
damage checkpoints) [172, 173]. The p130Rb protein level is
elevatedinquiescentcellsanddecreasedinproliferatingcells.
GSK3phosphorylatesp130RbduringG0,enhancingstability
ofp130Rb,butdoesnotaﬀectitsabilitytointeractwith E2F4
orcyclins[113]. ItisconceivablethatGSK3inhibition would
thus swing the balance towards p130Rb degradation and cell
proliferation.
3.3.7. PTEN. The PTEN tumor suppressor is a phos-
phatidylinositol D3-phosphatase that antagonizes the action
of phosphatidylinositol 3-kinase (PI 3K) and negatively
regulates cell growth and survival. CK2 phosphorylates
PTEN at Ser370 and Ser385 enabling GSK3to phosphorylate
Ser362 and Thr366 [128]. Expression of T366A mutant
PTEN reduces downstream PI 3K signaling to a higher
extent than wild-type PTEN suggesting that GSK3 inhibits
PTEN activity. In neuronal cell lines-leptin regulates PTEN
phosphorylation at Ser362 and Thr366 rather than inducing
PI3KactivityinordertocontroldownstreamPI3Ksignaling
[174]. Pharmacological inhibition of GSK3 would therefore
be predicted to antagonise the PI 3K signaling pathway
and reduce cell growth potential, although this remains to
be conclusively proven [128]. How this action of GSK3
interacts with that proposed for regulation of IRS1 described
above (where PI 3K signaling would be enhanced by GSK3
inhibition) is also unclear.
3.3.8. Heat Shock Factor (HSF)-1. Mammalian heat shock
genes are regulated at the transcriptional level by heat shock
factor-1 (HSF-1), a sequence-speciﬁc transcription factor.
HSF-1 exists as a latent cytoplasmic phosphoprotein but is
transformed by dephosphorylation to a nuclear protein that
controls the transcription of heat shock genes [175]. HSF-
1 is phosphorylated by GSK3 at Ser303, following priming
of Ser307 by ERK [68]. GSK3 thus represses the activity of
HSF-1, and in a manner reminiscent of c-Myc regulation
(Section 3.3.5 above) serum induction of ERK will prime
H S F - 1a tat i m ew h e r eG S K 3a c t i v i t yi sl o w ,p r e s u m a b l yt o
permita rapidrelocalisation ofHSF-1following reductionin
ERKsignaling. InhibitionofGSK3wouldthusbeexpected to
enhance the production of heat shock proteins.
3.3.9.Hypoxia-Inducible Transcription Factor(HIF) 1α. HIF-
1α is a transcription factor that is vital for the cellular
response to hypoxia; however it also responds to growth
factors and hormones following activation of PI 3K sig-
naling [176]. The inhibition or depletion of GSK3 induces
HIF-1α expression whereas the overexpression of GSK3
results in the opposite. These eﬀects are mediated through
phosphorylation of three serines in the oxygen-dependent
degradation domain of HIF-1α, and degradation occurs in
a VHL-independent manner [69]. Thus, phosphorylation
of HIF-1α by GSK3 is proposed to reduce HIF-1α stability,
and GSK3 inhibition (physiologically or pharmacologically)
would then promote the action of this transcription factor
and alter oxygen sensing and cell growth.
3.3.10. Eukaryotic Initiation Factor 2B (eIF2B). eIF2B is
a small G-protein that catalyses the exchange of guanine
nucleotidesoneIF2,animportantregulatorystepintheiniti-
ation of mRNA translation. GSK3 phosphorylates Ser535 of
eIF2B after a priming phosphorylation by DYRK at Ser539
[60–62]. Phosphorylation of these residues inhibits eIF2B
thereby reducing translation, and as such GSK3 inhibition
could enhance protein synthesis and cell growth.
3.3.11. Polycistin 2 (PC2). Polycystin-2 (PC2) is mutated in
15% of patients with autosomal dominant polycystic kidney
disease (ADPKD).It is a nonselective Ca2+-permeable cation
channel thought to function at both the cell surface and
ER. GSK3 phosphorylates Ser76 of PC2 in vitro and the
consensus recognition sequence for GSK3 (Ser76/Ser80) is
evolutionarily conserved down to lower vertebrates [121].
Inhibition of GSK3 redistributes PC2 from the lateral
plasma membrane pool into an intracellular compartment
in MDCK cells without a change in primary cilia localization
[121]. Hence, it appears that the surface localization of
PC2 is regulated by phosphorylation by GSK3, and this
contributes to the maintenance of normal glomerular and
tubular morphology.
3.3.12. Voltage-Dependent Anion Channel (VDAC). Trans-
formed cells are highly glycolyticand overexpress hexokinase
II (HXK II). HXK II binds to the mitochondria through an
interaction with VDAC, an abundant outer mitochondrial
membrane protein. The binding of HXK II to mitochondria
contributes to maintenance of cell viability. Phosphorylation
of VDAC by GSK3 prevents binding of HXK II promoting
dissociation of HXK II from the mitochondria [141]. Inhibi-
tion of PKB potentiates chemotherapy-induced cytotoxicity,
an eﬀect that is dependent on GSK3 activation (downstream
of PKB) as well as the reduced binding of HXK II to
the mitochondria [141]. Hence, enhancing GSK3 activity
toward VDAC may potentiate the eﬃcacy of conventional
chemotherapeutic agents.
3.3.13. Cytidine Triphosphate Synthetase (CTPS). CTPS cat-
alyzes the rate-limiting step in the de novo synthesis of
CTP. Phosphorylation of CTPS1 at Ser571 reduces its
activity in vitro, while phosphorylation of Ser571 in cells
is antagonised by the presence of serum [55]. Phosphory-
lation of Ser571 is reduced (with subsequent induction of
CTPS1 activity) in cells following incubation with either
the GSK3 inhibitor indirubin-3 -monoxime or GSK3β short
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production through the phosphorylation and inhibition of
CTPS.
3.3.14. Focal Adhesion Kinase (FAK). GSK3 can phospho-
rylate FAK at Ser722 [63]. Meanwhile, S722A mutation or
dephosphorylation of Ser722 by PP1 increases FAK kinase
activity, and cells expressing the S722A mutant FAK display
improved cell spreading and faster migration in wound-
healing and trans-well assays. The data proposes that GSK3
is a key regulator of FAK activity during cell spreading and
migration (and potentially metastasis).
3.4. GSK3 in Neurobiology
3.4.1. Microtubule Function. Neuronal connections are
formed during development by a precise and complex
pattern of axonal growth, guidance, and synaptogenesis.
To achieve this the cells must continually remodel the
cytoskeleton in response to external guidance cues that
include the Semaphorins, Wnts, and growth factors (for
review see [177–179]). Cytoskeletal reorganisation can be
accomplishedbycontrolofmicrotubuledynamicsand/orthe
actin cytoskeleton. Microtubule assembly and stability are
regulated in large part by the presence and the phosphory-
lation status of the microtubule-associated proteins (MAPs)
[180, 181]. Many of the MAPs are substrates for GSK3.
(1) Tau. Tau is a microtubule-associated protein encoded
by a single gene on chromosome 17 (MAPT). It is found
predominantly in cells of neuronal origin and regulates
microtubule assembly, a function that is inﬂuenced by gene
splicing (there are six possible isoforms of tau), as well as by
phosphorylation (phospho-tau has lower aﬃnity for micro-
tubules). Hyperphosphorylated tau is the major protein
constituent of neuroﬁbrillary tangles, one of the hallmarks
ofAlzheimer’sdisease. Around50phosphorylation siteshave
been identiﬁed on tau protein, many speciﬁcally associated
with neurodegenerative disease, and many of these are
known to inﬂuence its regulation of microtubule assembly.
Regulation of Tau phosphorylation in health and disease has
been covered extensively in recent reviews [182–185]a n di s
discussed in detail in a separate review within this issue.
(2) Collapsin Response Mediator Proteins (CRMP). CRMPs
are a family of ﬁve structurally homologous tubulin-binding
proteins implicated in multiple aspects of neuron develop-
ment and polarisation [49, 50, 186–192]. CRMP1, 2 and 4
are all substrates for GSK3 in vitro and in vivo [48, 49, 193],
being phosphorylated at 3 residues (Ser518, Thr514, and
Thr509)byGSK3subsequenttopriming byphosphorylation
at Ser522. Priming of CRMP1 and CRMP2 is performed
by CDK5 as neither of these phosphorylation events occurs
in tissue lacking CDK5, while priming of CRMP4 does not
require CDK5 [193]. Phosphorylation of CRMP2 by GSK3
r e g u l a t e sa x o ng r o w t ha sw e l la st h en u m b e ro fa x o n s[ 48,
49, 193], while phosphorylated CRMP2 binds less eﬃciently
to tubulin heterodimers. CRMP2 and CRMP4 are not phos-
phorylated at 518/514/509in neurons lacking GSK3β (either
genetic or pharmacological ablation) [11, 48], while GSK3β
phosphorylates these substrates more avidly than GSK3α in
vitro[11].CRMP2is more heavily phosphorylated in human
cortex from Alzheimer’s brain compared to age-matched
controls [194], and phosphorylated CRMP2 is found in
tangles[195].Phosphorylation ofCRMP4byGSK3mediates
dendrite development in response to inhibitory ligands such
as myelin [50]. The CRMPs are excellent substrates for GSK3
in vitro being phosphorylated at a relatively high rate and
stoichiometry compared to other GSK3 substrates, and are
completely dependent on priming.
(3) Microtubule-Associated Protein (MAP) 1B. MAP-1B, a
major component of the neuronal cytoskeleton, regulates
axonal growth potentially through its ability to bind to and
increase the stability of microtubules [196–198]. In contrast
to tau, phosphorylated MAP-1B binds to microtubules more
avidly than unphosphorylated MAP-1B. Phosphorylated
MAP-1B is present mainly in axons while unphosphorylated
MAP-1B is present in the cell body and dendrites suggesting
localization is regulated by this modiﬁcation (for review
see [199]). Moreover, the level of phosphorylated MAP-1B
increases during axonal extension declining to low levels
at the end of axonogenesis and a phosphorylated form
of MAP-1B is distributed across the axon in a gradient
fashion with the highest level at the growth cone [200–202].
GSK3 phosphorylates MAP-1B at Ser1260, Thr1265, and
Ser1388, the latter requiring priming at Ser1392 by DYRK.
Phosphorylation of these residues stabilizes the MAP-1B as
well as contributing to its higher aﬃnity for microtubules
[81–83]. GSK3 regulation of MAP1B is a vital link between
Wnt-7a signaling and axonal remodeling [81–83].
(4) MAP2C. The microtubule-associated protein 2 (MAP2)
proteins, like MAP-1B and tau, are abundant cytoskeletal
components predominantly expressed in neurons. MAP2 is
phosphorylated in vitro and in situ by GSK3 at Thr1620
and Thr1623, located in the proline-rich region of MAP2
[84]. Cotransfection of GSK3 and MAP2C in cells promotes
phosphorylation of MAP2C, a modiﬁcation that is sensitive
to the presence of lithium chloride (a nonselective inhibitor
of GSK3). Additionally, the formation of microtubule bun-
dles, which is observed after transfection with MAP2C,
is decreased when GSK3 is co-transfected [84]. Highly
phosphorylated MAP2C species are found predominantly
unbound to microtubules. These data suggests that GSK3-
mediated phosphorylation of MAP2C reduces its binding to
microtubules and co-ordinated phosphorylation of MAP2C,
tau, and MAP-1B by GSK3 is a major mechanism for
regulation of microtubule stability in neurons.
(5) Von Hippel-Lindau (VHL) Tumor Suppressor Gene. Inac-
tivation of the von Hippel-Lindau (VHL) tumor suppressor
gene is linked to the development of tumors of the eyes,
kidneys, and central nervous system. VHL encodes two gene
products, pVHL30 and pVHL19, of which one, pVHL30,
associates with microtubules(MTs) toregulate theirstability.
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a priming phosphorylation event at Ser72 (mediated in vitro
by CKI) regulates the ability of pVHL’s to stabilize (but not
bind) microtubules [142]. Hence pVHL can be added to the
list of GSK3 substrates involved in control of microtubule
dynamics.
(6) CLIP-Associating Protein (CLASP) 2. Actin and micro-
tubules are coupled structurally and distributed asymmet-
rically along the front-rear axis of migrating cells. CLIP-
associating proteins (CLASPs) accumulate near the ends of
microtubules, particularly at the front of migrating cells,
to control microtubule dynamics and cytoskeletal coupling.
Regional regulation of GSK3 is proposed to regulate the
distributionofCLASPs[45–47].IQGAP1is anactin-binding
protein, as well as a CLASP-binding protein. GSK3β directly
phosphorylates CLASP2 at Ser533 and Ser537 within the
IQGAP1 binding domain. Phosphorylation of these residues
dissociates CLASP2 from IQGAP1 and microtubules [47].
Overexpression of active GSK3β alters the distribution of
wild-type CLASP2 on microtubules, but not that of a non-
phosphorylatable CLASP2 mutant. CLASP2 phosphorylated
by GSK3 does not accumulate near the ends of micro-
tubules.Thus, phosphorylationofCLASP2byGSK3controls
the regional linkage of microtubules to actin ﬁlaments
and hence inﬂuences cell movement and axonal guidance
[47].
3.4.2. Presynaptic Function of GSK3—Dynamin I. GSK3
will phosphorylate the large GTPase dynamin I at Thr774
following priming at Thr778 by CDK5 [58]. The activity
of GSK3 is speciﬁcally required for activity-dependent bulk
endocytosis (ADBE), but not clathrin-mediated endocyto-
sis. Moreover the speciﬁc phosphorylation of Ser774 on
dynamin I by GSK3 is both necessary and suﬃcient for
ADBE. This demonstrates a role for GSK3 preparing synap-
tic vesicles for retrieval during elevated neuronal activity
[58].
3.4.3. Neurogenesis—Ngn2. The diﬀerentiation of neural
progenitors (neurogenesis) involves two coordinated steps:
the commitment to neuronal fate and the establishment
of cell-type identity [203]. As mentioned earlier, loss of
both GSK3 genes in the brain induces self-renewal of neu-
ronal progenitor cells, but reduces neurogenesis [152]. Two
conserved serine residues on the bHLH factor neurogenin-
2 (Ngn2), namely Ser231 and Ser234, are phosphorylated
during motor neuron diﬀerentiation [108]. This phospho-
rylation can be carried out by GSK3 in vitro,a l t h o u g h
it is not clear whether priming is required (either at
Ser234 or elsewhere), and phosphorylation facilitates the
interaction of Ngn2 with LIM homeodomain transcription
factors [108]. In Ngn2 knock-in mice in which these two
residues are mutated to alanines (insensitive to GSK3 regu-
lation), motor neuron speciﬁcation is impaired. Hence, this
phosphorylation-dependent cooperativity between Ngn2
and homeodomain transcription factors downstream of
GSK3 may contribute to neurogenesis and cell fate decisions
in the CNS [108], and could explain at least in part the
phenotype of the brain-speciﬁc GSK3 KO mouse [152].
3.4.4. GSK3 in Alzheimer’s Disease (Tau, APP, CRMP,
MARK, and DSCR1). Phosphorylation of the MAPs, tau
and CRMP2, at residues targeted by GSK3, is higher
in the brains of patients with Alzheimer’s disease than
age-matched controls. Indeed the phosphorylated forms
of these proteins are the main protein constituents of
neuroﬁbrillary tangles,implicatingexcessiveGSK3-mediated
phosphorylation of MAPs in tangle pathology. Interestingly
abnormal GSK3 activity has also been linked to amyloid
pathology.
The major component of senile plaques (an early and
important hallmark of AD) is the beta amyloid peptide,
Ab, a 39–43 amino acid fragment derived from proteolysis
of amyloid precursor protein (APP) by β-a n dγ-secretases
[204, 205]. Inhibition of cellular GSK3 by lithium or GSK3β
antisense oligonucleotides reduces Ab production in cells
without signiﬁcantly aﬀecting cellular APP levels or APP
maturation [28]. In addition, Ab production in the brain
of a mouse model of AD is reduced by dosing the animal
with lithium [28]. More speciﬁcally, GSK3 phosphorylates
recombinant APP at Thr743 (numbering for APP 770),
although whether this alters processing is not clear [27].
In neurons APP is highly phosphorylated at this site, but
Thr743 can be phosphorylated by a number of kinases,
including JNK, GSK3, and CDK5. In addition, JNK activity,
modulated by GSK3, enhances the traﬃc of phosphorylated
APP to nerve terminals and inhibition of GSK3 and JNK
restores calcium oscillations in a hAPP expressing neuronal
network [29]. In contrast to the wild-type hAPP, expression
of the hAPPT743A mutant in cells does not inhibit calcium
oscillations, and the proportion of this mutant APP at the
plasma membrane is signiﬁcantly less than wild-type hAPP.
Thus GSK3/JNK phosphorylation controls APP traﬃcking
at the plasma membrane and inhibits neuronal calcium
oscillations.
Among the many phosphorylation sites identiﬁed in
tau, Ser262 is a major site of abnormal phosphorylation
in AD brain. One kinase known to phosphorylate this
site is MARK2. GSK3 phosphorylates MARK2 in vitro at
Ser212, one of two reported phosphorylation sites (Thr208
and Ser212) found in the activation loop of MARK2.
Downregulation of either GSK3 or MARK2 by siRNAs
suppresses the level of phosphorylation of tau on Ser262
suggesting that GSK3 regulates Ser262 of tau indirectly
through phosphorylation and activation of MARK2 [85];
however, this has recently been disputed [86].
Calcineurin is a calcium/calmodulin-activated serine/
threonine phosphatase (also known as PP2B). Down syn-
drome candidate region 1 (DSCR1) is the mammalian
homologue of the yeast RCN family (more recently referred
to as calsipressins) that directly regulates calcineurin [206].
Calcineurin function is well characterized in yeast, where its
expression promotes growth in high calcium environments
by dephosphorylation of the Tcn1p transcription factor. It
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and skeletal and cardiac muscle growth and diﬀerentiation.
Hence, by regulating calcineurin, DSCR1 has the potential
to inﬂuence all of these processes. The DSCR1 gene was
isolated from the “Down syndrome candidate region”, and
in the brain, DSCR1 is predominantly expressed in neurons
within the cerebral cortex, hippocampus, substantia nigra,
thalamus, and medulla oblongata. DSCR1 mRNA levels
are three times higher in patients with extensive neu-
roﬁbrillary tangles (hallmark of AD) compared to controls
[207]. Similarly, postmortem brain samples from Down
syndrome patients (who develop AD pathology) also have
DSCR1 mRNA levels higher than controls. In addition,
exposure of cultured cells to the Ab(1–42) peptide increases
expression of DSCR1 [207]. Paradoxically, while increasing
Rcn1 expression can inhibit calcineurin signaling in fungal
and animal cells, endogenous levels can actually stimu-
late calcineurin signaling in yeast [130]. The stimulatory
eﬀect of yeast Rcn1 requires phosphorylation of a serine
residue (conserved in mammals) by a yeast homologue
of GSK3 (Mck1). Mutation of this serine in yeast Rcn1,
and the human homologue DSCR1, abolishes the stim-
ulatory eﬀects of Rcn1/DSCR1 on calcineurin signaling.
Therefore, in healthy cells, GSK3 may switch Rcn1/DSCR1
between stimulatory and inhibitory forms [130]. Whether
abnormal GSK3 regulation of DSCR1 contributes to the
pathophysiology of AD or Downs syndrome remains
unknown.
3.5. GSK3 in Development
3.5.1.WntSignaling-Beta Catenin. Oneofthebest-described
cellular functions of GSK3 is the regulation of canonical
Wnt signaling. This topic is reviewed in excellent detail
elsewhere [21, 208–210] and so will not be covered in
depth in this review. In short, GSK3β associates with a
large protein complex that includes adenomatous polyposis
coli (APC), axin, and β-catenin. All three of these proteins
are proposed as GSK3 substrates and phosphorylation of
each is proposed to regulate the stability of the complex
[21, 211, 212]. The phosphorylation of β-catenin by GSK3
is greatly enhanced by the presence of Axin, which acts as
as c a ﬀold for the other components [34]. Axin and APC
are also substrates of GSK3. Axin phosphorylation by GSK3
stabilizes the protein [35], while APC phosphorylation by
GSK3 enhances the interaction of β-catenin and APC [31].
GSK3 phosphorylates Ser33, Ser37, and Thr41 of β-catenin
following priming at Ser45by CKI[213, 214]. These residues
lie in a trCP motif and phosphorylation recruits SKP1-
cullin1-F-box (SCFβ-TrCP) E3 ligase complex followed by
degradation of β-catenin via the 26S proteasome [210].
Exposure of cells to Wnts reduces GSK3 activity in the
Axin complex (by disruption of protein:protein interactions
or phosphorylation of Thr380) resulting in dephosphory-
lation and stabilization of β-catenin, which translocates to
the nucleus to induce transcription in cooperation with
TCF transcription factors. Interestingly the pool of GSK3
associated with Wnt signaling appears distinct to that
associated with growth factor signaling [23], probably since
the mechanism of inhibition is distinct in each case and the
Wnt sensitive GSK3 is sequestered within microvesicles [24].
This targeting of SCFβ-TrCP to substrates of GSK3 may be
more widespread than currently appreciated and may allow
Wnts to alter the stability of a wide range of cellular proteins
[24].
3.5.2. Hedgehog (Hh) Signaling-Ci155. The Hh family of
secreted proteins controls cell growth and patterning in
development, while mutations in components of the Hh
signaling pathway are associated with increased human
disease [215]. Cubitus interruptus (Ci155) is a transcrip-
tional inducer ﬁrst identiﬁed as a mediator of Hh signaling
in Drosophila.E x p o s u r eo fDrosophila cells to Hh blocks
productionofatranscriptional repressor normally generated
byproteolyticcleavageofCi155[216].DeletionofGSK3(sgg
indrosophila) resultsinaccumulationofthefull lengthCi155
and the ectopic expression of Hh responsive genes including
decapentaplegic (dpp) and wingless (wg), suggesting GSK3
inhibition is part of Hh regulation of Ci155 processing.
Ci155 is phosphorylated by GSK3 at three sites (852 and
884/888) after priming (at 856 and 892, resp.) by protein
kinase A (PKA) [43, 44]. Mutation of these GSK3 target sites
in Ci155 blocks processing and prevents the production of
the repressor [43, 44]. Hence GSK3 acts in conjunction with
PKAto promote proteolyticprocessing ofCi155,switching it
from a transcriptional inducer to repressor. Hh may reduce
Ci155 proteolysis by inhibiting GSK3 and promoting Ci155
dephosphorylation.
3.5.3. Cardiomyocyte Development-Myocardin. Myocardin is
a muscle-speciﬁc transcription factor whose overexpression
induces hypertrophy in neonatal rat cardiomyocytes [99],
with increased cell size, total protein amount, and induction
of generationofatrial natriuretic factor (ANF).Myocardin is
phosphorylated by GSK3 at multiple sites in two regions of
the protein between Ser455 to Ser467 and Ser624 to Ser636
[99]. Myocardin-induced ANF transcription and increase
in total protein amount are enhanced by LiCl treatment
of cells, consistent with GSK3 inhibiting myocardin activ-
ity. A phosphorylation-resistant myocardin mutant (8xAla)
activated ANF transcription twice as potently as wild-type
myocardin [99]. Conversely, a phosphomimetic myocardin
mutant (8xAsp) was relatively transcriptionally inactive
compared to wild type, in the presence of GSK3 inhibitors.
Therefore, the GSK3-myocardin interaction regulates car-
diomyocyte hypertrophy.
3.5.4. Epithelial-Mesenchymal Transition-Snail. The epithe-
lial-mesenchymal transition (EMT) occurs during embry-
onic development and is triggered by Snail, a zinc-ﬁnger
transcription factor, which acts by repressing E-cadherin
transcription. Snail is highly unstable with a half-life
of about 25min. GSK3β binds to and phosphorylates
Snail at two consensus motifs including residues 97/101
and 108/112/116/120 [134]. Phosphorylation of the ﬁrst
motif regulates β-Trcp-mediated ubiquitination, whereas
phosphorylation of the second motif controls subcellular14 International Journal of Alzheimer’s Disease
Table 2: -GSK3 inhibition in vivo. Potential functional outcomes of pharmacologicalinhibition of GSK3.
Substrate group 1—Metabolic: Overall Eﬀect is anti-diabetic
GS Increase glycogen synthesis and glucose disposal (anti-diabetic)
Unknown Turn oﬀ hepatic glucose output (anti-diabetic)
CREB Reduce glucagon action (anti-diabetic)
IRS1 Stabilise IRS1 protein and enhance insulin action (anti-diabetic)
Inhibitor2 Inhibit PP1 (not clear if beneﬁcial)
Substrate group 2—Growth: Predicted eﬀect would be oncogenic, except for eﬀect on mdm2/p53 and PTEN
BCL3 Stabilise BCL3 (increased oncogenic potential)
c-jun Induce c-jun activity (increased oncogenic potential)
c-myc Stabilize c-myc protein (increased oncogenic potential)
Mcl-1 Stabilise Mcl-1 (antiapoptotic)
p130Rb Increase p130Rb degradation (cell cycle progression)
PTEN Decrease PI3K signaling(decrease growth factor signaling)
IRS1 Stabilise IRS1 and enhance PI3K signaling (increase growth)
HIF1a Stabilize HIF1a (could induce cell growth)
eIF2B Enhance protein translation (aid cell growth)
VDAC Enhance VDAC interaction with mitochondria (antiapoptotic)
CTPS Enhance CTP production (aid cell growth)
FAK Increase FAK activity (enhance cell spreading and migration)
Mdm2 Stabilise p53 (tumour suppression)
Substrate group 3—Alzheimer’s disease: Conducive to reducing AD pathology
Tau Reduce tangle formation(anti-AD?)
APP Reduce abeta production (anti-AD?)
CRMP2 Regulate axon outgrowth, reduce CRMP2 found in AD (anti-AD?)
MARK2 Reduce tau phosphorylation (anti-AD?)
Calcipressin Regulate calcineurin action (anti-AD?)
Substrate group 4—Wnt and Hh signaling: Enhanced eﬀect on Wnt and Hh signaling
b-catenin Induce b-catenin levels (induce wnt signaling)
Axin Reduce axin levels (induce wnt signaling)
APC Reduce APC b-catenin interaction (induce wnt signaling)
Ci155 Reduce proteolysis of Ci155 (enhanced Hh signaling)
Substrate group 5—Other possible detrimental eﬀects:
MAP1B Reduce MAP1B interaction with microtubules (Wnt7a resistance)
MAP2C Increase MAP2C interaction with microtubules (eﬀect not clear)
CLASP2 Alteration of actin-microtubule interaction (eﬀect not clear)
Dynamin I Reduced presynaptic ADBE (eﬀect not clear)
Ngn2 Impaired motor neuron designation (developmental?)
PC2 Relocalise PC2 (enhance polycystic kidney disease)
Myocardin Enhance mycardin action (cardiac hypertrophy?)
NFAT Nuclear localization(compromiseimmune system?)
Unknown Suppress IL-1β, IL-6, TNF, IL-12 (compromiseimmune system?)
Unknown Induction of IL-10 (compromiseimmune system?)
localization [134]. A variant of Snail (Snail-6SerAla), which
cannot be phosphorylated at these motifs, is much more
stable and resides exclusively in the nucleus to induce EMT.
Importantly, inhibition of GSK3 results in the upregulation
of Snail and downregulation of E-cadherin in vivo.T h u s ,
Snail and GSK3 function as a molecular switch leading to
EMT.
3.6. GSK3 in Immunology. There are many studies suggest-
ing that GSK3 plays a key role in both the innate and
adaptive immune systems (for recent paper see [217, 218]).
There are two main strands of evidence supporting this
function for GSK3: ﬁrstly that many cytokines and immune
stimuli regulate GSK3 activity, and secondly that inhibition
of GSK3 alters many aspects of the immune response.
Speciﬁcally, Toll-like receptors [219, 220], T cell receptor
[221], CD28 [221], and interleukin receptors [222]h a v ea l l
been shown to induce inhibitory phosphorylation of GSK3
in cells. In contrast, IFN-γ reduces phosphorylation and
activates GSK3 in TLR2-stimulated macrophages [223]o rInternational Journal of Alzheimer’s Disease 15
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Figure 2: Potential physiologicaland pathological eﬀects of phosphorylation of proposed GSK3 substrates.
RAW264.7 cells [224]. These studies place GSK3 upstream
of STAT3 and STAT1 in the IFN-γ signaling pathway, but
have not demonstrated that the STATs are direct targets
for GSK3. Inhibition of GSK3, using selective inhibitors
or shRNAi, decrease IFN-γ-induced inﬂammation and this
actionrequirestheSrchomology-2domaincontainingphos-
phatase 2 (SHP2) [224]. Inhibition of GSK3 activates SHP2,
p r e v e n t i n gS T A T 1a c t i v a t i o ni nl a t es t a g eI F N - γ stimulation;
however, like STATs, SHP2 is not a direct target for GSK3
[224].
Interestingly, pharmacological reduction of GSK3 (ad-
mittedly in some cases not with very selective inhibitors)
suppresses the production of IL-1β, IL-6, TNF, and IL-
12, whilst enhancing production of IL-10 by TLRs [219].
Despite these major eﬀects of GSK3 on cytokine production
the speciﬁc substrates of GSK3 responsible remain elusive.
NFAT, C/EBPβ, and CREB are transcription factors known
to regulate many of these genes and both are proposed
substrates of GSK3 (Table 1(a)); however these proteins
have not been studied in the context of immunological
regulation by GSK3. GSK3 inhibition increases the nuclear
translocation of several mediators of the immune response,
including these transcription factors [217]. GSK-3 phospho-
rylates a series of conserved serines on NFAT,at least in vitro,
and phosphorylation of these sites inhibits DNA binding
and promotes nuclear exit of NFAT (thereby opposing
calcineurin signaling) [105–107]. It remains to be seen
how many of the immune eﬀects of GSK3 inhibition are
mediated through direct regulation of these transcription
factors.
4.Physiological Outcomeof GSK3Inhibition
The literatureindicatesthatinhibitionofGSK3invivowould
reduce the phosphorylation of dozens of proteins (Table 1)
and inﬂuence a wide range of cellular processes (Figure 2),
including cell growth, diﬀerentiation, survival, and commu-
nication. GSK3 inhibition would then be predicted to have
numerous unwanted side-eﬀects (Table 2). In particular, the
potential oncogenicity of GSK3 inhibition is a major worry,
and detrimental eﬀects on the immune system, heart, and
development are all possible (Table 2). Taken together with
the lethality of genetic ablation of just one isoform of GSK3
(GSK3β), and the important role of GSK3 in Wnt and
growth factor signaling, it is perhaps not surprising that
despite the huge eﬀort to develop potent inhibitors of GSK3,
none have actually made it into Phase 2 clinical trials.
However, it seems rather premature at this time to
discount inhibition of GSK3 as a beneﬁcial therapeutic
avenue. There is currently a lack of published evidence
that truly speciﬁc GSK3 inhibitors, at concentrations that
produce GSK3 inhibition, are harmful to healthy organisms,
yetthereisastudydemonstratingeﬃcacyatglucoselowering
inamodelofT2DMwithnoreportedtoxicsideeﬀects[159].16 International Journal of Alzheimer’s Disease
There are perhaps three major issues that should be
addressed to establish whether GSK3 inhibitors should be
pursued further for therapeutic potential.
Firstly, how harmful is conditional ablation of GSK3 in
adult animals? GSK3 inhibitors would not be used from
birth, and very few pharmaceuticalsachieve 100% inhibition
of their targets, hence it seems unlikely that the pathways
responsible for the lethality of the GSK3β knockout or those
involvedin embryonicdevelopmentwould beofrelevance in
the treatment of adults for diabetes or Alzheimer’s disease.
Secondly, how many of these reported substrates are
actually aﬀected by speciﬁc GSK3 inhibitors in vivo?A s
discussedinthispaperveryfewofthesubstratesinTable 1(a)
have convincing evidence establishing them as bona ﬁde
GSK3 substrates, while it has not yet been proven that
the phosphorylation (never mind proposed function) of
most of the substrates listed in Table 1(b) is signiﬁcantly
aﬀectedbyspeciﬁcGSK3inhibitioninvivo.Acompr ehensive
analysis of animals receiving eﬃcacious doses of speciﬁc
GSK3inhibitors may show that very few of these proteins are
functionally aﬀected by such pharmaceuticals.
Finally, most studies that aimed at identifying GSK3
substrateshavechronicallydeletedGSK3(genetically,siRNAi
or high-dose inhibitor). Animals lacking one allele of each
GSK3isoformhave a much lesssevere phenotype,suggesting
partial loss of GSK3 even chronically from birth is not
oncogenic. In addition, physiological regulation of GSK3 is
normally both partial and transient. For example insulin
treatment of cells rarely inhibits GSK3 more than 50% and
activityreturnstonormalinafewhours,whileWntsignaling
only regulates a very speciﬁc pool of GSK3. In addition
many of the key processes regulated by GSK3 have feedback
mechanisms to overcome abnormal regulation so proposed
side eﬀects may not materialize as predicted. It is quite likely
that only transient inhibition of GSK3 (backto normal levels
of GSK3 activity rather than complete ablation) would be
required for many of the beneﬁcial eﬀects of GSK3 inhibi-
tion. Therefore there is scope for more elegant intervention
of GSK3 function to achieve beneﬁcial responses, without
producing complete and chronic inhibition.
One would hope that improved knowledge of GSK3
biology would aid in the developmentof beneﬁcial interven-
tions. Others have suggested that drugs aimed at the phos-
phate binding pocket of GSK3 would preferentially inhibit
phosphorylation of primed substrates, and therefore reduce
potentialside eﬀects.However, Table 1(b)wouldsuggest that
most substrates of GSK3 do require a priming event. Other
possibilitiesincludeisoformspeciﬁcintervention,buttodate
thereisonlytantalizing evidenceforsubstratepreferenceand
little evidence for substrates that are completely speciﬁc to
o n eG S K 3i s o f o r m .H o w e v e rc h a n g i n gt h er a t i oo fG S K 3
isoform expression in speciﬁc tissues may still alter substrate
phosphorylation patterns. Possibly the most promising area
is the concept of substrate selective inhibition, where a
speciﬁc pool of GSK3 could be targeted (or avoided). It has
beenknownforsome time that GSK3exists inthe Axin-APC
complex, and this “GSK3 pool” is distinct from that targeted
by growth factors [23, 24]. If other GSK3 complexes exist
then the substrates listed in Table 1(b) could be subdivided
by the GSK3 complex that regulates them. Inhibition of a
GSK3 containing complex would then have a more speciﬁc
outcome than global GSK3 inhibition.
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